82-44-0

应用筛选条件

关键词:'82-44-0'

显示 31-36 共 36 条结果关于 "82-44-0" 范围论文

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Gerald S Falchook et al.

The Lancet. Oncology, 13(8), 782-789 (2012-07-19)

MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation and induces apoptosis. We aimed to analyse safety, efficacy, and genotyping data for the oral, small-molecule MEK inhibitor

Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis.

Ze-Dong Wang et al.

The lancet. HIV, 4(4), e177-e188 (2017-02-06)

Worldwide, 30% of the world's population have antibodies to the intracellular protozoan parasite Toxoplasma gondii and about 36·7 million people are infected with HIV, but little is known about the prevalence of co-infection with T gondii and HIV. We aimed

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

José Baselga et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(13), 1484-1491 (2012-03-14)

Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer. Patients were randomly assigned to first-

Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.

Catherine A Koss et al.

The lancet. HIV, 7(4), e249-e261 (2020-02-23)

Optimal strategies for pre-exposure prophylaxis (PrEP) engagement in generalised HIV epidemics are unknown. We aimed to assess PrEP uptake and engagement after population-level HIV testing and universal PrEP access to characterise gaps in the PrEP cascade in rural Kenya and

Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR.

Joshua M Barnett et al.

Investigative ophthalmology & visual science, 48(2), 907-915 (2007-01-26)

The efficacy of three matrix metalloproteinase (MMP) inhibitors with various selectivities (Ro-31-9790, AG3340, and DPC-A37668) was investigated in a rat model of retinopathy of prematurity, to examine the roles of MMP-2 and -9 in retinal neovascularization. The susceptibilities of MMP-2(-/-)

Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.

Shozo Yamada et al.

Journal of neurosurgery, 121(6), 1462-1473 (2014-09-23)

The aim of this study was to analyze clinicopathological characteristics and treatment outcomes in a large single-center clinical series of cases of thyrotropin (TSH)-secreting pituitary adenomas. The authors retrospectively reviewed clinical, pathological, and treatment characteristics of 90 consecutive cases of

2/2